The morbidity costs of air pollution through the Lens of Health Spending in China

This study is one of the first to present causal evidence of the morbidity costs of fine particulates (PM2.5) for all age cohorts in a developing country, using individual-level health spending data from a basic medical insurance program in Wuhan, China. Our instrumental variable (IV) approach uses...

Full description

Saved in:
Bibliographic Details
Published inJournal of population economics Vol. 36; no. 3; pp. 1269 - 1292
Main Authors Zhang, Xin, Zhang, Xun, Liu, Yuehua, Zhao, Xintong, Chen, Xi
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2023
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This study is one of the first to present causal evidence of the morbidity costs of fine particulates (PM2.5) for all age cohorts in a developing country, using individual-level health spending data from a basic medical insurance program in Wuhan, China. Our instrumental variable (IV) approach uses thermal inversion to address potential endogeneity in PM2.5 concentrations and shows that PM2.5 imposes a significant impact on healthcare expenditures. The two-stage least squares (2SLS) estimates suggest that a 10 μg/m 3 (micrograms per cubic meter) reduction in monthly average PM2.5 leads to a 2.36% decrease in the value of health spending and a 0.79% decline in the number of transactions at pharmacies and healthcare facilities. Also, this effect, largely driven by spending at pharmacies, is more salient for males and children, as well as middle-aged and older adults. Moreover, our estimates may provide a lower bound on individuals’ willingness to pay, amounting to CNY 43.87 (or USD 7.09) per capita per year for a 10 μg/m 3 reduction in PM2.5.
ISSN:0933-1433
1432-1475
DOI:10.1007/s00148-023-00948-y